Kamil Wisniewski, MD, PhD

Department of Hematology, Instutute of Hematology and Transfusion Medicine, Poland

Poster(s):

• 1406 - Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult Leukemia Group

• 1423 - MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)